ROS1+ lung cancer patients in United Kingdom: we need your help!

To all ROS1+ non-small cell lung cancer (NSCLC) patients in the United Kingdom (UK):

Please help advocate for coverage of crizotinib (Xalkori) for ROS1+ NSCLC through the UK’s national health system.  The Roy Castle Lung Cancer Foundation is putting together a submission on behalf of ROS1+ patients, and they are looking for patient experience quotes, preferably from the UK.  They do not need personal details.

If you are interested in sharing your ROS1+ patient experience, please contact
Nicola Forrest (Support Services Manager for Roy Castle Lung Cancer Foundation) by one of the methods below:

She will get in touch with you after Thursday February 15.

Thanks for your help!